<!DOCTYPE html>
<html>
<head>
<title>Refpages</title>
<link rel="stylesheet" href="refstyle.css">
</head>

<body>

<!-- refpage 28---------------------------------------------------------------------------------------------------------->
<div class = "title">Anticholinerge middelen</div>

<div class = "source">
<div class = "quote">
Anticholinerge middelen<br>
Lijst van valrisico-verhogende medicaties (p 63)
</div><div class = "ref" name="1">
Nederlandse Vereniging voor Klinische Geriatrie. Preventie van valincidenten bij ouderen. <a href="https://web.archive.org/web/20200918072601/https://richtlijnendatabase.nl/richtlijn/preventie_van_valincidenten_bij_ouderen/startpagina_-_preventie_van_valincidenten.html">https://richtlijnendatabase.nl/richtlijn/preventie_van_valincidenten_bij_ouderen/startpagina_-_preventie_van_valincidenten_bij_ouderen.html</a>
</div>
</div>

<div class = "source">
<div class = "quote">
Anticholinergics (Table 2: Fall-risk increasing drugs (FRIDs) according to the preliminary (September 2019) European consensus list.)
</div><div class = "quote">
Item 26: Drugs with anticholinergic properties (e.g. antihistamines, antidepressants, antipsychotics, antispasmodics) (cfr. Table 1) + Known dementia/ Cognitive impairment Increased anticholinergic medication burden may worsen cognitive and behavioural function; Increased risk of adverse CNS effects. 1st Re-evaluate whether indication is still present, if not: discontinue therapy; 2nd If therapy is necessary: discuss non-pharmacological options. Prefer switching to safer drug with the same indication with no or less anticholinergic activity (cfr. Table 1); 3rd If not possible: consider dose reduction and limit duration of use.
</div><div class="ref" name="7">
GheOP3S-tool draft 3 
</div>
</div>

<div class = "source">
<div class = "quote">
Bij spasmen van het maag-darmkanaal gaat de voorkeur uit naar ondersteunende maatregelen zoals dieet en geruststelling. Het effect van farmacotherapie is vaak teleurstellend. Indien men toch hiertoe besluit dan spelen de mogelijke bijwerkingen een belangrijke rol bij de keuze, aangezien het (povere) resultaat van de diverse middelen nauwelijks van elkaar verschilt.
</div><div class = "ref" name="65">
<a href="https://web.archive.org/web/20201126204237/https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/s/scopolaminebutyl">https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/s/scopolaminebutyl</a>
</div>
</div>

<div class = "source">
<div class = "quote">
Medications with high anticholinergic activity are more fall-risk-increasing than weak anticholinergics. Risk difference is related to the variation in sedative effects.
</div><div class="ref" name="10">
Lotta J Seppala, Mirko Petrovic, Jesper Ryg, Gulistan Bahat, Eva Topinkova, Katarzyna Szczerbinska, Tischa J M van der Cammen, Sirpa Hartikainen, Birkan Ilhan, Francesco Landi, Yvonne Morrissey, Alpana Mair, Marta Guti&eacute;rrez-Valencia, Marielle H Emmelot-Vonk, Mar&iacute;a &Aacute;ngeles Caballero Mora, Michael Denkinger, Peter Crome, Stephen H D Jackson, Andrea Correa-P&eacute;rez, Wilma Knol, George Soulis, Adalsteinn Gudmundsson, Gijsbertus Ziere, Martin Wehling, Denis O&acute;Mahony, Antonio Cherubini, Nathalie van der Velde, STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs, Age and Ageing, 2020;, afaa249, https://doi.org/10.1093/ageing/afaa249
</div>
</div>


</body>